<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04962035</url>
  </required_header>
  <id_info>
    <org_study_id>2006INF</org_study_id>
    <nct_id>NCT04962035</nct_id>
  </id_info>
  <brief_title>Alprem RTF Neurocognitive Follow-Up (FU) Study</brief_title>
  <acronym>AlpremFU</acronym>
  <official_title>Neurocognitive Scores of Predominantly Formula Fed Preterm Infants in Early Childhood Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nestlé</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nestlé</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a follow-up study of a recently completed trial (17.14.INF) evaluating the growth of&#xD;
      pre-term infants. Enrolled children will undergo neurocognitive assessments at 18- and&#xD;
      24-months of corrected age (CA).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a follow-up study of a recently completed multi-center, prospective, single-arm,&#xD;
      open-label interventional trial (17.14.INF - Alprem RTF: NCT03728764) evaluating the growth&#xD;
      of pre-term infants receiving a two-stage PTF feeding system while in the neonatal care unit&#xD;
      and continuing until 30 days post-discharge.&#xD;
&#xD;
      Enrolled children will undergo neurocognitive assessments at 18- and 24-months of corrected&#xD;
      age (CA). The timing of the cognitive assessments aligns with routine check-up visits and&#xD;
      reflect the period at which developmental delays may first become evident.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 26, 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Bayley-III scores at 24 months</measure>
    <time_frame>24 months of CA</time_frame>
    <description>Bayley Scales of Infant and Toddler Development, third edition (Bayley-III) cognitive score at 24 months of corrected age (CA). Composite scores range 40-160, with a mean of 100 and SD of 10 points. A composite score of 70 or less is an indication of a delay in child neurocognitive development.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bayley-III scores at 18 months</measure>
    <time_frame>18 months of CA</time_frame>
    <description>Bayley Scales of Infant and Toddler Development, third edition (Bayley-III) cognitive score at 18 months of corrected age (CA). Composite scores range 40-160, with a mean of 100 and SD of 10 points. A composite score of 70 or less is an indication of a delay in child neurocognitive development.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight</measure>
    <time_frame>At enrollment, 18 and 24 months of CA</time_frame>
    <description>Child weight (g)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length/height</measure>
    <time_frame>At enrollment, 18 and 24 months of CA</time_frame>
    <description>Child length/height (cm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Head circumference</measure>
    <time_frame>At enrollment, 18 and 24 months of CA</time_frame>
    <description>Child head circumference (cm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Child temperament scores</measure>
    <time_frame>At 18 and 24 months of CA</time_frame>
    <description>Parent-reported child temperament questionnaire validated specifically for children between the ages of 18 and 36 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Developmental Milestone scores</measure>
    <time_frame>At 18 and 24 months of CA</time_frame>
    <description>Parent-reported achievements of specific age-appropriate milestones (yes/no responses to child performing specific milestones or not)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of healthcare usage</measure>
    <time_frame>At 18 and 24 months of CA</time_frame>
    <description>Retrospective parent-reported recall of the number of healthcare usage and hospitalizations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Feeding patterns</measure>
    <time_frame>At 18 and 24 months of CA</time_frame>
    <description>Feeding practice outcomes collected retrospectively at each visit via a parent-reported questionnaire related to breastfeeding duration, prevalence of formula feeding, and age at initiation of complementary feeding</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Cognitive Developmental Delay</condition>
  <arm_group>
    <arm_group_label>Alprem RTF Brain Follow-up</arm_group_label>
    <description>Neurocognitive Follow-up of children previously having participated in the Alprem RTF study</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Neurocognitive Follow-up</intervention_name>
    <description>Standard clinical and parent-reported outcomes on cognitive development, temperament and overall health conditions.</description>
    <arm_group_label>Alprem RTF Brain Follow-up</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Infants who have previously participated in the 17.14.INF Alprem RTF study are eligible to&#xD;
        participate, wherein preterm infants of gestational age ≥ 27 weeks and ≤ 32 weeks with body&#xD;
        weight &lt;1500g and appropriate for gestational age (AGA) as defined by weight ≥10 percentile&#xD;
        and ≤90 percentile on the Fenton growth chart had been enrolled.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Infants / children born prematurely who were enrolled into the original clinical trial&#xD;
             and who are less than 24 m of CA.&#xD;
&#xD;
          2. Having obtained his / her parents' (or his or her legally accepted guardian written&#xD;
             informed consent and having evidence of personally signed and dated informed consent&#xD;
             document indicating that the child's parent(s) / legal guardian has been informed of&#xD;
             all pertinent aspects of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1. Infants identified retrospectively as not meeting the inclusion or exclusion criteria&#xD;
        for the original study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>17 Months</minimum_age>
    <maximum_age>25 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Cecilia Fumero</last_name>
    <phone>+41 21 785 8328</phone>
    <email>cecilia.fumero@rdls.nestle.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Klinika Chorob Dzieci, Uniwersytecki Szpital Dzieciecy</name>
      <address>
        <city>Krakow</city>
        <zip>30-663</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Przemko Przemko Kwinta, Prof.</last_name>
      <phone>+48 12 658 02 12</phone>
      <email>kwintap@mp.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Univerzitna nemocnica Martin</name>
      <address>
        <city>Martin</city>
        <zip>3659</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mirko Zibolen, Prof.</last_name>
      <phone>+421 905781085</phone>
      <email>zibolen.mirko.sen@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fakultna nemocnica s poliklinikou Nove Zamky</name>
      <address>
        <city>Nove Zamky</city>
        <zip>940 34</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Klaudia Demova, Dr.</last_name>
      <phone>+421 907899133</phone>
      <email>klaudia.demova@nspnz.sk</email>
    </contact>
  </location>
  <location_countries>
    <country>Poland</country>
    <country>Slovakia</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 29, 2021</study_first_submitted>
  <study_first_submitted_qc>July 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 14, 2021</study_first_posted>
  <last_update_submitted>July 5, 2021</last_update_submitted>
  <last_update_submitted_qc>July 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

